Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future. - Test2 - elhamkhani - TriplyDB

Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.

Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.

http://www.wikidata.org/entity/Q38810514

about

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14.The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.Ribosome biogenesis mediates antitumor activity of flavopiridol in CD44+/CD24- breast cancer stem cells.Cyclin-dependent kinase activity is required for type I interferon production.Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation.Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis.CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6

P2860

Q38662999-25680187-B05D-45E8-8DE6-F5180A3326F9 Q39055609-F6FFBD3B-FBA0-4392-BE25-29EDB35C3D2C Q39402106-D166FBC8-B384-4703-9663-512473A3CD66 Q47121115-71B77443-4383-4396-BBC7-F22C33F1BFED Q50054859-8D450553-6DBF-4A3D-A3FC-2FB5C5665AF7 Q50105972-CC491A9C-4D66-4587-A831-B2A179482189 Q52673244-EF0C5E9C-F354-4B49-BBA8-EE39E68C9D97 Q54978831-55512B92-A087-4663-9CEC-C2D0547828AC Q55361350-685A2FD1-A5D1-41B1-946A-D999D8EE41A6 Q57176702-75DFF6F4-F233-469C-A921-CB0A1C4F9C03 Q58786576-B4E474A7-9F95-4157-AF5D-E0FF5A650EF2

P2860

Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.

http://www.wikidata.org/entity/Q38810514

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cyclin-Dependent Kinase Inhibi ...... er: Past, Present, and Future.

@en

type

label

Cyclin-Dependent Kinase Inhibi ...... er: Past, Present, and Future.

@en

prefLabel

Cyclin-Dependent Kinase Inhibi ...... er: Past, Present, and Future.

@en

P1433

Q38810514-C4F09AFE-D9CF-418F-9507-E2B0130BE510

P1476

Q38810514-6A98B6C9-6C1B-49CE-A030-309A64403CE1

P2093

Q38810514-3C48E2EB-D215-40BA-BE82-5E045B6FDF06

Q38810514-5A49AB08-217D-4644-9279-840A5B3EE065

Q38810514-8A47CAE3-45B6-4E9C-ADA7-5DDA96DE1209

P2860

Q38810514-0D9C6234-8383-4644-B573-FC7499B6A03A

Q38810514-20B0BBAF-D6D0-43BF-89CB-1C84D6584C62

Q38810514-2A973AA8-A7C5-4A48-843A-FF9E6706B6FA

Q38810514-2B766D90-5995-4C4D-9A47-11A14A7CD8D7

Q38810514-3E1FF86D-9870-46C6-9D05-4CB8B3D535BC

Q38810514-4C2F9708-0CA9-4C6A-AB22-71C7E8E14659

Q38810514-4C881DC3-0FAC-465C-AF7E-0A6D6F58CCC7

Q38810514-4C8BADC2-B47E-48E3-8BF3-83B29BC0BAE8

Q38810514-5069598E-FD80-453B-B253-0E359C86525B

Q38810514-5C660A83-D3E4-4107-84D0-46B5F27A6E54

P304

Q38810514-6200194C-AE58-4D21-9136-0FDA7414D2B4

P31

Q38810514-FBF4EF09-2E25-4A7C-A84D-20060D2B9CB6

P356

Q38810514-D81FEE55-62FE-480F-A5E4-9A549616045F

P407

Q38810514-ED658783-AABC-4370-A5FD-C0117C8942B4

P433

Q38810514-5C7CCB2E-5ACB-408C-B7B6-F59471B37215

P478

Q38810514-DCE8BBC4-A32A-4F21-980C-B336010328F3

P577

Q38810514-DE3A0738-1776-4787-86EC-D8C022469F91

P698

Q38810514-AA1802D6-537F-494D-958F-53E32FF9DB89

P356

P1433

Pharmacotherapy

P1476

Cyclin-Dependent Kinase Inhibi ...... er: Past, Present, and Future.

@en

P2093

Adam J DiPippo

http://www.w3.org/2001/XMLSchema#string

Chad M Barnett

http://www.w3.org/2001/XMLSchema#string

Neelam K Patel

http://www.w3.org/2001/XMLSchema#string

P2860

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Cyclin-dependent kinase pathways as targets for cancer treatment

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

The history and future of targeting cyclin-dependent kinases in cancer therapy.

Pharmacological inhibitors of cyclin-dependent kinases.

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

The Role of CDK4/6 Inhibition in Breast Cancer.

P304

652-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1756

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27087139

http://www.w3.org/2001/XMLSchema#string